Askgene Pharma Inc. is a dynamic, clinical-stage biopharmaceutical company committed to advancing healthcare through the discovery, development, and commercialization of innovative antibody therapeutics and cell-based therapies. With a primary focus on oncology and immunological diseases, Askgene Pharma leverages cutting-edge science and a deep understanding of disease biology to create next-generation treatments. Their pipeline includes promising candidates designed to address unmet medical needs and improve patient outcomes globally. The company emphasizes a science-driven approach, fostering a culture of innovation and collaboration to bring transformative medicines to patients.
Primary US corporate operations, research and development (R&D) center, and clinical development activities.
Modern laboratory facilities equipped for antibody discovery, protein engineering, cell line development, and process development. Strategically located in a prominent Southern California biotech hub.
A collaborative, innovative, and science-driven environment focused on addressing critical unmet medical needs. Employees are typically engaged in cutting-edge research and development in a fast-paced, results-oriented setting common in clinical-stage biotech.
Serves as the central hub for Askgene Pharma's US operations and a key site for its global R&D strategy, spearheading the development of its therapeutic pipeline for North American and international markets.
Askgene Pharma maintains a strategic global presence with key operational and R&D centers in Camarillo, California, USA, and Shanghai, China. This dual-hemisphere approach allows the company to leverage diverse talent pools, research capabilities, and access to global markets. Askgene Pharma conducts clinical trials internationally and supports functions such as research, development, clinical operations, and business development across these major biotechnology hubs to advance its mission of delivering innovative therapies worldwide.
3601 Calle Tecate
Camarillo
CA
USA
Address: Building 7, Lane 66, Huatuo Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, China
Acts as a crucial operational and R&D hub for Askgene in Asia, tapping into the region's growing biotech talent pool and infrastructure to accelerate its global drug development programs.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, ASKGENE PHARMA, INC.' leadership includes:
ASKGENE PHARMA, INC. has been backed by several prominent investors over the years, including:
No major publicly announced executive hires or exits for the core leadership team have been prominently identified in the last 12 months (approximately May 2023 - May 2024). The current executive team appears stable based on public information. A key appointment of Dr. Joe Zuo as SVP, Head of Clinical Development & CMO occurred in early 2023.
Discover the tools ASKGENE PHARMA, INC. uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Askgene Pharma likely follows common corporate email address patterns. A frequently observed format for companies of this nature, and suggested by available data, is the first initial of the first name followed by the full last name.
flast@askgenepharma.com
Format
jhai@askgenepharma.com
Example
85%
Success rate
PR Newswire • January 30, 2024
Askgene Pharma announced that the first patient has been dosed in its US-based Phase I clinical trial for ASKG915. ASKG915 is a potential first-in-class Claudin 18.2 antibody-drug conjugate (ADC) being developed for the treatment of advanced gastrointestinal cancers and other solid tumors expressing Claudin 18.2....more
PR Newswire • February 2, 2023
Askgene Pharma successfully closed an oversubscribed $60 million Series B financing round. The financing was co-led by Eight Roads and F-Prime Capital, with participation from existing and new investors. The proceeds are intended to advance the clinical development of Askgene's innovative therapeutic pipeline, including ASKG915 (Claudin18.2 ADC) and ASKG712 (PD-1/IL-2a bispecific antibody), and to bolster its R&D capabilities....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including ASKGENE PHARMA, INC., are just a search away.